Symptoms, risk, screening and diagnostic confirmation

Detect Neuroendocrine Tumors is about choosing the right test for the right risk.

A NET detection guide covering functioning and non-functioning NETs, carcinoid syndrome, insulinoma hypoglycemia, chromogranin A limits, 5-HIAA, CT/MRI, EUS/endoscopy, gallium DOTATATE PET/CT and Ki-67 grade.

Screening reality Symptoms not to ignore

Educational, not personal medical advice. Flushing, chronic unexplained diarrhea, wheeze, recurrent ulcers, severe or recurrent low blood sugar, unexplained liver lesions or a pancreatic/bowel mass should raise the possibility of NET in the right context.

Functioning

insulinoma can cause dangerous hypoglycemia.

Silent

non-functioning NETs may grow large before detection.

5-HIAA

helps mainly serotonin-secreting carcinoid tumors.

DOTATATE

gallium PET/CT can localize SSTR-positive NETs.

Brief outline

What neuroendocrine tumors means.

Neuroendocrine tumors can arise in bowel, pancreas, lung and other sites. Functioning NETs secrete hormones and may announce themselves; non-functioning NETs may grow silently until they are large, metastatic or found incidentally.

Continuous glucose monitor showing low glucose in insulinoma — A glucose reading of 1.7 mmol/L is about 31 mg/dL, or 31 mg/100 mL: profoundly low and capable of causing confusion, collapse or seizures.

Detection frame

Screening is for people without symptoms. Diagnosis is for symptoms, abnormal examination, family history, imaging findings or abnormal labs. The same test can be sensible in one setting and misleading in another.

Do not ignore

Symptoms and signs not to ignore.

Flushing/diarrheaClassic carcinoid syndrome, often with liver metastases.

HypoglycemiaInsulinoma can cause very low blood sugar, confusion, collapse or seizures.

Recurrent ulcersGastrinoma/Zollinger-Ellison pattern.

Incidental liver lesionsNET metastases can be hypervascular.

Vague pain/weight lossNon-functioning NETs may present late by size or spread.

Wheeze or heart valve diseaseCan occur in carcinoid syndrome.

Risk and genetics

Demographics, risks and genetics.

MEN1Pancreatic/duodenal NET risk, including insulinoma/gastrinoma.

VHL/NF1/TSCSelected inherited risks.

Family historyRare but important.

Age/siteRisk patterns vary by primary site.

Prior gastric diseaseType 1 gastric NET relates to autoimmune gastritis.

Most sporadicMany NETs have no inherited cause.

Screening

Who should actually be screened?

There is no average-risk population screening. Genetic syndromes and known precursor conditions require specialist surveillance.

Biochemistry

5-HIAA urine/plasma

Useful for serotonin-secreting carcinoid tumors; diet/drugs can interfere.

Insulinoma

Glucose, insulin, C-peptide during hypoglycemia

Confirms inappropriate insulin secretion before localization.

Marker

Chromogranin A

Can be elevated by PPIs, kidney disease and other causes; poor as blind screening.

Imaging

CT/MRI multiphase

Finds primary tumors and liver metastases.

Receptor imaging

Ga-68 DOTATATE PET/CT

A gallium DOTATATE scan shows somatostatin-receptor-positive disease; some insulinomas need additional or different localization.

Pathology

Biopsy with Ki-67 grade

Grade and differentiation drive prognosis and treatment.

Images, labs and tissue

Useful tests and what they can miss.

Detection usually needs a chain: recognizing the syndrome, proving the biochemistry at the time of symptoms, localizing the lesion, then confirming grade and biology when tissue is needed. Insulinoma is a good example: the glucose, insulin and C-peptide pattern matters before the scan is interpreted. A meter reading of 1.7 mmol/L converts to about 31 mg/dL (31 mg/100 mL), which is dangerously low.

Insulin and C-peptide laboratory results during insulinoma assessment — High insulin and C-peptide in the wrong context supports endogenous hyperinsulinism.

Laboratory glucose result showing severe hypoglycemia — The key is documenting low plasma glucose with inappropriate insulin secretion, not doing blind NET marker screening.

Pros, cons and controversy

Benefits, harms and the false-positive problem.

NET blood markers can mislead badly if used as screening in low-risk people. The benefit is highest when symptoms, imaging or inherited risk point to the diagnosis. Functioning tumors such as insulinoma may be detected because the hormone syndrome is dramatic; non-functioning NETs are riskier for delay because they can simply grow.

Neuroendocrine Tumors detection trials DetectCancer.org hub

Sources and trials

Good starting points.

NCI pancreatic NET diagnosisDiagnosis, imaging, lab testing and staging for pancreatic NETs, including islet-cell tumors. ClinicalTrials.gov NET detectionNET imaging and biomarker trials.